Natixis Karuna Therapeutics, Inc. Transaction History

Natixis

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$161.01 - $317.85 $6.72 Million - $13.3 Million	41,737 New	41,737 $13.2 Million
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $8 Million - $12.2 Million	-85,142 Reduced 94.45%	5,000 $633,000
Q1 2022 May 13, 2022	BUY	$98.9 - $132.37 $5.64 Million - $7.55 Million	57,010 Added 172.07%	90,142 $11.4 Million
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $3.67 Million - $5.28 Million	33,132 New	33,132 $4.34 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.